Discovery of Protein Biomarkers

Detection of diseases through bodily fluids such as blood, is increasingly becoming the mainstream approach for clinical screening and diagnosis. Currently, there are already 100-200 plasma proteins approved by the FDA as disease biomarkers.

Clinical Trial Patient Screening & Stratification

Large-scale plasma proteomics discovery aids in more accurate patient screening, understanding patient characteristics, and identifying additional biomarkers. This enhances the accuracy and reliability of clinical trials, providing more guidance and information for clinical practice.

New Target
Discovery

Proteins are key to cellular functions and reflect gene expression levels. Recent advances in mass spectrometry-based proteomics have opened new possibilities for studying disease mechanisms and discovering therapeutic targets.

Drug Efficacy Prediction and Assessment

Proteomics is widely employed in clinical drug efficacy assessment. Through proteomic techniques, the impact of drugs on proteins within the human body can be thoroughly studied, enabling the evaluation of drug efficacy and side effects.